Geron Corp
Closed
SectorHealthcare
1.52 -1.94
Overview
Share price change
24h
Min
1.51
Max
1.56
Income | -13M -17M |
|---|---|
Sales | 5.6M 57M |
EPS | -0.02 |
Profit margin | -29.019 |
Employees | 258 |
EBITDA | -16M -12M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +179.35% upside |
Next Earnings | 4 lis 2026 |
|---|
Market Cap | 162M 983M |
|---|---|
Previous open | 3.46 |
Previous close | 1.52 |
Geron Corp Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Geron Corp Forecast
Price Target
By TipRanks
179.35% upside
12 Months Forecast
Average 4.33 USD 179.35%
High 6 USD
Low 3 USD
Based on 4 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.